Further detailed studies are required in order to determine how ABT-263 promotes apoptosis in response to agents targeting tumour metabolism and how these agents affect the balance of pro and anti-apoptotic BCL-2 proteins in pediatric glioma cells. This evidence concerns the gene BCL2 and glioma.